Currently, there are no targeted drugs available for TP53, and studies have shown that EGFR-mutant NSCLC patients with co-occurring TP53 mutations are more prone to resistance against EGFR-TKIs. This evidence concerns the gene EGFR and non-small cell lung carcinoma.